NR565 ADVANCED PHARMACOLOGY
FINAL EXAM PREP (VERIFIED AND
CORRECT Q & A) SATISFACTION
GUARANTEED 2026/2027
CHAMBERLAIN
1. A patient with a history of heart failure and a reduced ejection fraction (HFrEF) is currently
taking an ACE inhibitor, a beta-blocker, and a loop diuretic. Which of the following
medications is most appropriate to add to improve survival outcomes?
A. Diltiazem
B. Amlodipine
C. Spironolactone
D. Digoxin
Answer: C
Conceptual Explanation: Aldosterone antagonists like spironolactone are proven to
reduce mortality in patients with HFrEF already on standard therapy. Calcium channel
blockers like diltiazem are often avoided in HFrEF due to negative inotropic effects.
2. When initiating therapy with an ACE inhibitor for a patient with diabetic nephropathy,
which laboratory finding would require the practitioner to discontinue or adjust the dose?
A. Serum potassium level of 5.7 mEq/L
,B. Serum potassium level of 4.2 mEq/L
C. Serum creatinine increase of 10% from baseline
D. Decrease in proteinuria
Answer: A
Conceptual Explanation: ACE inhibitors can cause hyperkalemia. A potassium level above
5.5 mEq/L generally requires intervention or discontinuation. A minor increase in
creatinine (up to 30%) is often expected and acceptable.
3. A patient is prescribed Warfarin for atrial fibrillation. They are starting a course of
Sulfamethoxazole/Trimethoprim for a UTI. What is the expected interaction?
A. Decreased Warfarin effect and increased risk of clotting
B. No significant interaction
C. Decreased effectiveness of the antibiotic
D. Increased Warfarin effect and increased risk of bleeding
Answer: D
Conceptual Explanation: Bactrim (Sulfamethoxazole/Trimethoprim) is a potent inhibitor
of CYP2C9, which metabolizes the more active S-isomer of warfarin, leading to significantly
increased INR and bleeding risk.
, 4. A 65-year-old patient with Chronic Obstructive Pulmonary Disease (COPD) requires a long-
acting bronchodilator. Which medication class is considered first-line for maintenance
therapy in this patient?
A. Short-acting beta agonists (SABA)
B. Systemic corticosteroids
C. Inhaled corticosteroids (ICS) alone
D. Long-acting muscarinic antagonists (LAMA)
Answer: D
Conceptual Explanation: LAMAs (like tiotropium) are preferred for COPD maintenance
because they effectively reduce exacerbations and improve lung function; ICS is usually not
used as monotherapy in COPD.
5. Which of the following statements is true regarding the mechanism of action of SGLT2
inhibitors in the treatment of Type 2 Diabetes?
A. They inhibit glucose reabsorption in the proximal renal tubule.
B. They increase peripheral glucose uptake in the muscles.
C. They stimulate insulin release from pancreatic beta cells.
D. They delay carbohydrate absorption in the gut.
Answer: A
FINAL EXAM PREP (VERIFIED AND
CORRECT Q & A) SATISFACTION
GUARANTEED 2026/2027
CHAMBERLAIN
1. A patient with a history of heart failure and a reduced ejection fraction (HFrEF) is currently
taking an ACE inhibitor, a beta-blocker, and a loop diuretic. Which of the following
medications is most appropriate to add to improve survival outcomes?
A. Diltiazem
B. Amlodipine
C. Spironolactone
D. Digoxin
Answer: C
Conceptual Explanation: Aldosterone antagonists like spironolactone are proven to
reduce mortality in patients with HFrEF already on standard therapy. Calcium channel
blockers like diltiazem are often avoided in HFrEF due to negative inotropic effects.
2. When initiating therapy with an ACE inhibitor for a patient with diabetic nephropathy,
which laboratory finding would require the practitioner to discontinue or adjust the dose?
A. Serum potassium level of 5.7 mEq/L
,B. Serum potassium level of 4.2 mEq/L
C. Serum creatinine increase of 10% from baseline
D. Decrease in proteinuria
Answer: A
Conceptual Explanation: ACE inhibitors can cause hyperkalemia. A potassium level above
5.5 mEq/L generally requires intervention or discontinuation. A minor increase in
creatinine (up to 30%) is often expected and acceptable.
3. A patient is prescribed Warfarin for atrial fibrillation. They are starting a course of
Sulfamethoxazole/Trimethoprim for a UTI. What is the expected interaction?
A. Decreased Warfarin effect and increased risk of clotting
B. No significant interaction
C. Decreased effectiveness of the antibiotic
D. Increased Warfarin effect and increased risk of bleeding
Answer: D
Conceptual Explanation: Bactrim (Sulfamethoxazole/Trimethoprim) is a potent inhibitor
of CYP2C9, which metabolizes the more active S-isomer of warfarin, leading to significantly
increased INR and bleeding risk.
, 4. A 65-year-old patient with Chronic Obstructive Pulmonary Disease (COPD) requires a long-
acting bronchodilator. Which medication class is considered first-line for maintenance
therapy in this patient?
A. Short-acting beta agonists (SABA)
B. Systemic corticosteroids
C. Inhaled corticosteroids (ICS) alone
D. Long-acting muscarinic antagonists (LAMA)
Answer: D
Conceptual Explanation: LAMAs (like tiotropium) are preferred for COPD maintenance
because they effectively reduce exacerbations and improve lung function; ICS is usually not
used as monotherapy in COPD.
5. Which of the following statements is true regarding the mechanism of action of SGLT2
inhibitors in the treatment of Type 2 Diabetes?
A. They inhibit glucose reabsorption in the proximal renal tubule.
B. They increase peripheral glucose uptake in the muscles.
C. They stimulate insulin release from pancreatic beta cells.
D. They delay carbohydrate absorption in the gut.
Answer: A
